Dual roles of Nrf2 in cancer

被引:545
作者
Lau, Alexandria [1 ]
Villeneuve, Nicole F. [1 ]
Sun, Zheng [1 ]
Wong, Pak Kin [2 ]
Zhang, Donna D. [1 ]
机构
[1] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[2] Univ Arizona, Dept Aerosp & Mech Engn, Tucson, AZ 85721 USA
关键词
Nrf2; Keap1; ARE; Glutamate cysteine ligase; Glutathione peroxidase; Thioredoxin reductase; Peroxiredoxin; Glutathione S-transferase; NAD(P)H quinone oxidoreductase-1; Heme oxygenase; MRP;
D O I
10.1016/j.phrs.2008.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In response to oxidative stress, the transcription factor NF-E2-related factor 2 (Nrf2) controls the fate of cells through transcriptional upregulation of antioxidant response element (ARE)-bearing genes, including those encoding endogenous antioxidants, phase II detoxifying enzymes, and transporters. Expression of the Nrf2-dependent proteins is critical for ameliorating or eliminating toxicants/carcinogens to maintain cellular redox homeostasis. As a result, activation of the Nrf2 pathway, by naturally-occurring compounds or synthetic chemicals at sub-toxic doses, confers protection against subsequent toxic/carcinogenic exposure. Thus, the use of dietary compounds or synthetic chemicals to boost the Nrf2-dependent adaptive response to counteract environmental insults has emerged to be a promising strategy for cancer prevention. Interestingly, recent emerging data has revealed the "dark" side of Nrf2. Nrf2 and its downstream genes are overexpressed in many cancer cell lines and human cancer tissues, giving cancer cells an advantage for survival and growth. Furthermore, Nrf2 is upregulated in resistant cancer cells and is thought to be responsible for acquired chemoresistance. Therefore, it may be necessary to inhibit the Nrf2 pathway during chemotherapy. This review is primarily focused on the role of Nrf-2 in cancer, with emphasis on the recent findings indicating the cancer promoting function of Nrf2 and its role in acquired chemoresistance. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:262 / 270
页数:9
相关论文
共 158 条
[1]   Multidrug Resistance-Associated Protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine Sulfoximine [J].
Akan, Ilhan ;
Akan, Selma ;
Akca, Hakan ;
Savas, Burhan ;
Ozben, Tomris .
CANCER CELL INTERNATIONAL, 2005, 5 (1)
[2]   Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2 [J].
Aleksunes, Lauren M. ;
Slitt, Angela L. ;
Maher, Jonathan M. ;
Augustine, Lisa M. ;
Goedken, Michael J. ;
Chan, Jefferson Y. ;
Cherrington, Nathan J. ;
Klaassen, Curtis D. ;
Manautou, Jose E. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2008, 226 (01) :74-83
[3]   Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust [J].
Aoki, Y ;
Sato, H ;
Nishimura, N ;
Takahashi, S ;
Itoh, K ;
Yamamoto, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2001, 173 (03) :154-160
[4]   The thioredoxin system in cancer [J].
Arner, Elias S. J. ;
Holmgren, Arne .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) :420-426
[5]   Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase-1 [J].
Asher, G ;
Lotem, J ;
Cohen, B ;
Sachs, L ;
Shaul, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (03) :1188-1193
[6]   Curcurnin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element [J].
Balogun, E ;
Hoque, M ;
Gong, PF ;
Killeen, E ;
Green, CJ ;
Foresti, R ;
Alam, J ;
Motterlini, R .
BIOCHEMICAL JOURNAL, 2003, 371 :887-895
[7]  
Ban N, 1996, CANCER RES, V56, P3577
[8]   The GI-GPx gene is a target for Nrf2 [J].
Banning, A ;
Deubel, S ;
Kluth, D ;
Zhou, ZW ;
Brigelius-Flohé, R .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (12) :4914-4923
[9]   Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours:: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy [J].
Basu, S ;
Brown, JE ;
Flannigan, GM ;
Gill, JH ;
Loadman, PM ;
Martin, SW ;
Naylor, B ;
Scally, AJ ;
Seargent, JM ;
Shah, T ;
Puri, R ;
Phillips, RM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (05) :703-709
[10]  
Ben-Dor A, 2005, MOL CANCER THER, V4, P177